

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated 28 December 2023 (the “Prospectus”) issued by WellCell Holdings Co., Limited 經緯天地控股有限公司 (the “Company”).

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilising) Rules (Chapter 571W of the Laws of Hong Kong). This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Share Offer described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or a solicitation of an offer to buy securities in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any applicable state securities laws, and may not be offered, sold, pledged or transferred in the United States unless pursuant to an exemption from, or in a transaction that is not subject to, the registration requirements of the U.S. Securities Act and any applicable state securities laws. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act. There will be no public offering of the securities of the Company in the United States.



WellCell Holdings Co., Limited

經緯天地控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2477)

**END OF STABILISATION PERIOD, NO STABILISING ACTION
AND
LAPSE OF THE OVER-ALLOTMENT OPTION**

END OF STABILISATION PERIOD AND NO STABILISING ACTION

The announcement is made pursuant to Section 9(2) of the Securities and Futures (Price Stabilising) Rules (Chapter 571W of the Laws of Hong Kong).

The Company announces that the stabilisation period in connection with the Share Offer ended on Thursday, 8 February 2024, being the 30th day after the last day for lodging of applications under the Public Offer.

Reference is made to the announcement of the Company dated 11 January 2024. The Sole Overall Coordinator (for itself and on behalf of the Placing Underwriters) confirmed that there had been no over-allocation of the Shares in the Placing. Therefore, the Over-allotment Option had not been exercised. The Company was informed by the Stabilising Manager that no stabilising action was taken by the Stabilising Manager or any person acting for it during the stabilisation period.

LAPSE OF THE OVER-ALLOTMENT OPTION

The Company further announces that the Over-allotment Option has not been exercised by the Sole Overall Coordinator (for itself and on behalf of the Placing Underwriters) during the stabilisation period and lapsed on Thursday, 8 February 2024. Accordingly, no Share was or will be issued by the Company under the Over-allotment Option.

PUBLIC FLOAT

Immediately after the end of the stabilisation period, the Company complies and will continue to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules whereby at least 25% of the Company's total number of issued Shares at all times be held by the public.

By order of the Board
WellCell Holdings Co., Limited
Jia Zhengyi
Chairman

Hong Kong, 8 February 2024

As at the date of this announcement, the directors of the Company are as follows:

Executive Directors:

Mr. Jia Zhengyi (*Chairman*)

Ms. Liu Ping

Mr. Cong Bin

Independent non-executive Directors:

Mr. Wu Wing Kuen

Dr. Leung Kwong Sak

Mr. Yu Chi Wing

Non-executive Director:

Mr. Lin Qihao